MarketWatch

(PMZN) SCIENTURE'S Arbli(TM) Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

The MarketWatch News Department was not involved in the creation of this content. Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to ...
Yahoo Finance

EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives

Scienture Holdings, Inc. (NASDAQ:SCNX) announced on Tuesday that Arbli (losartan potassium) Oral Suspension, 10 mg/mL, has been added to the formularies of key national payors, expanding access ...
Business Insider

SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tablets U.S. losartan market totals $256M annually with 71M prescriptions, ...
Seeking Alpha

SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli ™ as the first FDA-approved ready-to-use oral suspension “This represents a paradigm ...
The Globe and Mail

SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli ™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 16, 2025 ...